Leishmania donovani develops resistance to drug combinations.
Drug combinations for the treatment of leishmaniasis represent a promising and challenging chemotherapeutic strategy that has recently been implemented in different endemic areas. However, the vast majority of studies undertaken to date have ignored the potential risk that Leishmania parasites could...
Saved in:
Main Authors: | Raquel García-Hernández (Author), José Ignacio Manzano (Author), Santiago Castanys (Author), Francisco Gamarro (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2012-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fitness of Leishmania donovani parasites resistant to drug combinations.
by: Raquel García-Hernández, et al.
Published: (2015) -
Metabolic variation during development in culture of Leishmania donovani promastigotes.
by: Ana Marta Silva, et al.
Published: (2011) -
Hemophagocytosis in Experimental Visceral Leishmaniasis by Leishmania donovani.
by: Ayako Morimoto, et al.
Published: (2016) -
Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection.
by: Sandip Mukherjee, et al.
Published: (2012) -
LABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of Leishmania.
by: Jenny Campos-Salinas, et al.
Published: (2013)